Cerenome (PSTV) Cash from Investing Activities (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Cash from Investing Activities of -$8.5 million for Q1 2026, down 339.83% year-over-year from $3.6 million in Q1 2025, and down 692.29% quarter-over-quarter from -$1.1 million in Q4 2025.
Cerenome (PSTV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Cash from Investing Activities for 17 consecutive years, with -$8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 339.83% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$12.9 million (down 6749.21% YoY), while the FY2025 annual figure was -$854000.0, up 79.23% from the prior year.
- Cash from Investing Activities fell to -$8.5 million in Q1 2026 per PSTV's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $3.6 million in Q1 2025 and bottomed at -$8.5 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$848058.8 across 5 years, with a median of -$42000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 34463.64% — and 2025, when it soared 14511.11%.
- Plus Therapeutics' Cash from Investing Activities stood at -$11000.0 in 2022, then sank by 281.82% to -$42000.0 in 2023, then soared by 252.38% to $64000.0 in 2024, then slumped by 1782.81% to -$1.1 million in 2025, then plunged by 692.29% to -$8.5 million in 2026.
- Business Quant data shows PSTV's Cash from Investing Activities at -$8.5 million in Q1 2026, -$1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.53 Mn |
| Mar 31, 2026 | -8.53 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -3.80 Mn |
| Mar 31, 2024 | -364,000.00 |
| Mar 31, 2024 | -364,000.00 |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |